Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. (IPSC) received a Schedule 13G filing from Commodore Capital and related parties. The filing reports beneficial ownership of 13,043,478 shares of Century Therapeutics common stock, representing 7.1% of the outstanding class.
The position consists of 8,695,652 shares of common stock plus 4,347,826 additional shares underlying a warrant. Ownership percentages are based on 179,337,686 shares outstanding as of January 9, 2026, plus the warrant shares. Commodore Capital LP, Commodore Capital Master LP, and individuals Robert Egen Atkinson and Michael Kramarz share voting and dispositive power over the reported shares.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics, which is why the stake is reported on a Schedule 13G instead of a control‑oriented Schedule 13D.
Century Therapeutics, Inc. received a Schedule 13G filing showing a significant passive ownership position by TCG Crossover funds and Chen Yu in its common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their respective general partners, each report beneficial ownership of 8,877,215 shares of common stock, representing 4.9% of the class. Chen Yu, as managing member of both general partners, reports aggregate beneficial ownership of 17,754,430 shares, or 9.9% of the common stock, based on 179,337,686 shares outstanding as of January 9, 2026.
The filing notes additional Pre-Funded Warrants and Common Stock Warrants that could be settled in more shares but are excluded because they are not exercisable within 60 days and are subject to a 9.99% Beneficial Ownership Limitation. The reporting parties certify the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics, Inc. received a Schedule 13G reporting that Deep Track Capital and related entities beneficially own 13,486,400 shares of its common stock, representing 7.34% of the class. The filing aggregates positions held by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and individual reporting person David Kroin, all with shared voting and dispositive power over these shares.
The ownership calculation is based on 183,685,512 shares, including common stock outstanding and additional common stock issued, plus 4,347,826 shares underlying warrants that are subject to a 9.99% beneficial ownership limitation. The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics, Inc. filed a current report to notify investors that it has updated its corporate slide presentation. The revised investor presentation, dated January 12, 2026, is attached as Exhibit 99.1 and may be used by company representatives in meetings with investors from time to time.
The company states that the information in this report and the attached presentation is being furnished rather than filed under the securities laws, meaning it is not automatically incorporated into other securities filings unless specifically referenced.
Century Therapeutics entered into a private placement with institutional investors to raise approximately $135.0 million in gross proceeds. The company agreed to sell 92,030,595 shares of common stock and/or pre-funded warrants for 25,360,704 shares, plus warrants for 58,695,648 shares, at a purchase price of $1.15 per share and accompanying warrant, or $1.1499 per pre-funded warrant and accompanying warrant. Pre-funded warrants are exercisable immediately at $0.0001 per share and do not expire, while common warrants are exercisable immediately at $2.60 (or $2.599 for a pre-funded warrant) and expire on the earlier of 30 days after public announcement of initial Phase 1 data for CNTY-813 or three years after closing. The company plans to use the net proceeds primarily to fund development of CNTY-813 and for working capital and general corporate purposes.
Century Therapeutics, Inc. reported that board member Carlo Rizzuto, Ph.D., has resigned from its board of directors, effective December 18, 2025. The company states that Dr. Rizzuto’s decision to step down was not due to any disagreement with the company regarding its operations, policies, or practices. Century Therapeutics publicly thanked Dr. Rizzuto for his distinguished service and contributions to the company.
Century Therapeutics, Inc. reported an insider transaction by a director who also serves as President and CEO. On 12/12/2025, this person acquired 52,000 shares of common stock in a transaction coded “P” at a weighted average price of $0.5837 per share.
After this purchase, the insider beneficially owns 3,322,990 common shares with direct ownership. The filing notes that the shares were bought in multiple trades between $0.577 and $0.5838 per share, and that all profits from the reported transactions will be disgorged to the company under applicable requirements.
Century Therapeutics, Inc.'s president and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/10/2025, 463 shares of common stock were withheld at $0.526 per share to cover tax obligations triggered by the vesting of restricted stock units. After this transaction, the executive directly owns 3,270,990 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. disclosed that one of its directors submitted an initial insider ownership statement indicating no beneficial ownership of company securities. The report shows no direct or indirect holdings of common stock or derivative securities, so the director reported zero beneficial ownership as of the event date of 12/09/2025.
Century Therapeutics (IPSC) Chief Scientific Officer reported an automatic sale of company stock related to tax withholding. On 11/20/2025, the reporting person sold 5,462 shares of common stock at $0.501 per share in a transaction labeled as a sale to cover tax obligations from vesting restricted stock units. After this transaction, the reporting person beneficially owned 987,027 shares directly and 10,697 shares indirectly through a trust. The filing notes that the trust-held shares are disclaimed as beneficially owned except to the extent of any pecuniary interest.